Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here we go. Gonna SOAR. More phase 3 studies and results coming. GWPH has all the patents.
For men: check out prostate cancer trial. CBD curing cancer. Miracle drugs coming.
It's starts today. Earnings gonna be horrific. Better take profits. Buy back in at $350
Interesting post from another board that could have some big implications here....
I was wondering if and when this was going to start happening. GW could be effectively cornering the CBD market with their numerous patents and FDA trials. The two bit, penny stock, hemp hustling scumbags days could finally be numbered. There is a massive untapped market for GW to corner here if the FDA continues with stuff like this.
I've warned other penny players that this day might come. I know there's two sides to this argument as well, but for now it appears that GW has a strong upper hand if they choose to wave it.
Thanks stockmasterflash. Call options just got a bit more juicy. wink
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121769664
February 4, 2016
WARNING LETTER
VIA OVERNIGHT DELIVERY
RETURN RECEIPT REQUESTED
Brandon Nolte
HealthyHempOil.com
Double Minors
823 Congress, Suite 150 #561
Austin, TX 78767
Dear Brandon Nolte:
This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.healthyhempoil.com in January 2016 and has determined that you take orders there for the products “Herbal Renewals Gold CBD Oil,” “Herbal Renewals CBD Oil Spray,” “Entourage Occam’s Razor Hemp e Liquid,” “Plus CBD Oil Hemp Salve Relief,” and “Hempotion Cannabidiol Extract Tincture,” which you claim contain cannabidiol (CBD). FDA also reviewed your social media websites at https://twitter.com/healthyhempoil and https://www.facebook.com/healthyhempoil/. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.
Although you market “Herbal Renewals Gold CBD Oil” and “Herbal Renewals CBD Oil Spray” as dietary supplements, FDA has concluded based on available evidence that CBD products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the Act [21 U.S.C. § 321(ff)(3)(B)(ii)]. Under that provision, if an article (such as CBD) has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD.
The existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex[1]. FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under FDA’s regulations (21 CFR 312.2), unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the Act. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the Act, but you may present FDA with any evidence that has bearing on this issue.
Examples of claims observed on your website www.healthyhempoil.com that establish the intended use of your products include, but may not be limited to, the following:
On the webpage titled “Herbal Renewals: Gold CBD Oil (255mg-15.3g CBD)”:
“Alleviates anxiety”
“Strong analgesic properties”
“CBD has been proven to be effective against inflammation, anxiety and chronic pain.”
“Studies that are currently underway explore the possibility that CBD is also a powerful natural solution for other serious health problems including symptoms of heart disease, diabetes, cancer . . . .”
On the webpage titled “Herbal Renewals: CBD Oil Spray (100mg CBD)”:
“Introducing the world’s best herbal remedy for anxiety: CBD Spray by Herbal Renewals is here to dissolve your worries away with the powerful, all-natural healing properties of CBD oil.”
“Herbal Renewals CBD Spray is hailed as the best herbal remedy for anxiety thanks to CBD’s powerful anxiolytic (anti-anxiety) properties.”
“Cannabidiol has been proven to be a powerful natural remedy against inflammatory diseases, chronic pain, and anxiety without known side effects . . . .”
“[N]ew and emerging research suggests that CBD may also be a potent natural remedy for a wide range of other ailments, including heart disease, . . . diabetes . . . ..”
On the webpage titled “Entourage: Occam’s Razor Hemp e Liquid (100mg CBD)”:
“[S]cientific studies have shown potential health benefits for people with:
o Anxiety disorders
o Inflammation pain
o Stress
o Nausea”
“There is also some evidence that CBD may have anti-cancer properties . . . .”
“CBD has also shown promise in diminishing chemotherapy-induced nausea.”
On the webpage titled “Plus CBD Oil: Hemp Salve Relief (50mg CBD)”:
“Recent scientific studies have showcased CBD’s beneficial effects against inflammation, pain, and anxiety.”
“Anti-inflammatory”
“Natural analgesic”
On the webpage titled “Hempotion: Cannabidiol Extract Tincture (100-250mg CBD)”
“[W]ill alleviate all kinds of anxiety and inflammation problems.”
“Alleviates anxiety”
“Strengthens immune system”
On the webpage titled “The Ultimate Resource Page for Cannabidiol (CBD)”:
“CBD has been shown to be effective for decreasing anxiety and helping in a number of inflammation-related problems, including arthritis and other inflammatory ailments as well as multiple sclerosis.”
“CBD is also proven to inhibit the growth of the MRSA bacterium (a strain of staphylococcus resistant to antibiotics), which causes several difficult-to-treat infections.”
“CBD is currently used to treat symptoms of anxiety and certain cases of inflammation.”
“It has also been shown to be effective in treating a wide range of other ailments. These studies, though still in early stages, imply that CBD could be used to treat . . . multiple sclerosis, and numerous inflammatory diseases, as well as inhibit the growth of certain forms of cancer.”
On the webpage titled “Cannabidiol Anxiety Research”:
“As many studies show, CBD seems to have anxiolytic properties (inhibits stress and anxiety) without any psychoactive effects, making it a potentially versatile alternative to a number of existing anxiolytic drugs.”
On the webpage titled “Cannabidiol Antipsychotic Research”:
“CBD seems to have fewer side effects, is more cost effective (when compared to other medications with similar effects), and has been shown to be superior to most conventional antipsychotic medications.”
On the webpage titled “Cannabidiol Cancer Research”:
“[N]umerous recent studies have verified that cannabidiol exhibits some inhibitory effects on several types of cancer including breast cancer, colon cancer, certain types of brain tumors, leukemia and others.”
“CBD has been shown to induce programmed cell death in breast cancer cells. . . .”
“CBD seems to render certain cancerous cells more susceptible to chemotherapy agents.”
On the webpage titled “Cannabidiol Pain Relief Research”:
“CBD is currently regarded as one of the safest cannabinoids and it has been shown to be effective against a number of cancer-related pains in numerous clinical trials.”
“CBD and other cannabinoids have also been shown to have effective analgesic properties for terminal cancer patients . . . .”
Examples of claims observed on your social media accounts that establish the intended use of your products include, but may not be limited to, the following:
https://twitter.com/healthyhempoil
July 14, 2015 posting – “Treating Schizophrenia with Cannabidiol . . .”
https://www.facebook.com/healthyhempoil/
June 5, 2015 posting – “An increasing body of evidence also suggests that cannabidiol, one of the major non-psychoactive cannabinoids in all types of cannabis plants, is a good natural remedy for anxiety.”
Your products “Herbal Renewals Gold CBD Oil,” “Herbal Renewals CBD Oil Spray,” “Entourage Occam’s Razor Hemp e Liquid,” “Plus CBD Oil Hemp Salve Relief,” and “Hempotion Cannabidiol Extract Tincture” are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.
A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Your products “Herbal Renewals Gold CBD Oil,” “Herbal Renewals CBD Oil Spray,” “Entourage Occam’s Razor Hemp e Liquid,” “Plus CBD Oil Hemp Salve Relief,” and “Hempotion Cannabidiol Extract Tincture” are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Herbal Renewals Gold CBD Oil,” “Herbal Renewals CBD Oil Spray,” “Entourage Occam’s Razor Hemp e Liquid,” “Plus CBD Oil Hemp Salve Relief,” and “Hempotion Cannabidiol Extract Tincture” fail to bear adequate directions for their intended uses and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].
The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.
You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.
Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to:
U.S. Food and Drug Administration
CDER/OC/OUDLC
10903 New Hampshire Ave, WO51
Silver Spring, MD 20993-0002
FDAADVISORY@fda.hhs.gov
Sincerely,
/S/
Ilisa Bernstein, Pharm.D., J.D.
Deputy Director
Office of Compliance
Center for Drug Evaluation and Research
Cc:
Healthy Hemp Oil
6411 Bella Vista Dr. Ste 1
Rockford, MI 49341
Double Minors LLC
803 Wagonwheel Lane
West Chester, PA 19380
___________________________________________
[1] See “Sativex Commences US Phase II/III Clinical Trial in Cancer Pain,” available at http://www.gwpharm.co.uk/Commences%20US%20Phase%20IIIII%20Clinical%20Trial.aspx and “GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome,” available at http://www.gwpharm.com/GW%20Pharmaceuticals%20Receives%20Investigational%20New%20Drug%20IND%20from%20FDA%20f
Report TOS
Small Cap Wired
Target Price Outlook GW Pharmaceuticals Plc (NASDAQ:GWPH)
by Small Cap Contributor — April 8, 2016
Currently, shares of GW Pharmaceuticals Plc (NASDAQ:GWPH) have a consensus target price of $148.833. The analyst providing the highest target price estimate according to data provided by Zacks Research, is presently $172. The analyst with the lowest target on the stock anticipates shares touching $130. Target price projections may vary from analyst to analyst. Wall Street analysts might use resistance and support levels to help evaluate where the stock may be moving in the future. Zacks Research also provides recommendations from street analysts that cover the stock. These recommendations fall on a simple scale provided by Zacks Research. Using information provided from various polled analysts, Zacks Research reports shares of GW Pharmaceuticals Plc with a current ABR of 1.08. This number is based on a recommendation scale where the ratings range from a 1 to a 5. Following this scale, a 1 would indicate a Strong Buy while a 5 would indicate a Strong Sell.
We can also take a look at some company earnings per share or EPS information. Earnings per share is the segment of profit for a company that is allocated to every outstanding share of a company’s common stock. Earnings per share numbers can serve as an indicator for the profitability of a certain company. EPS is widely considered to be one of the most important factors when evaluating the price of a share. A Zacks consensus currently shows Street analysts projecting the company to post per share earnings of $-1.85. For the period ending 2015-12-31, GW Pharmaceuticals Plc reported actual EPS of $-1.2. This number was $0.64 away from analyst predictions, providing a surprise factor of 34.78%. The company is expected to next release earnings on or around 2016-05-09.
GW Pharmaceuticals Plc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.
1 Strange Fruit That 'Destroys' Diabetes
Diabetes Protocol
You'll Probably Quit Your Job After This Video. You Can Earn $10,000 Every Week!
Quick Cash System
Dad Discovers Unique Method To Regrow Hair (Do This Daily)
Hairloss Protocol
7 Amazing Tricks To Get Any Woman Into Bed
Stealth Attraction
Hurry Up Before This Video Gets Banned!
Cash Code
Weird 2-Minute Trick Restores Perfect Hearing
Reverse Hearing Loss
Is Your Acid Reflux Killing You?
Reflux Relief
Guys Are Following These 7 Easy Steps To Get Laid Without Fail!
Stealth Attraction
Tiny Trick KILLS Erectile Dysfunction
Ed Protocol
Is It Possible To Get Rid Of Herpes For Good?
Erase Herpes
Tinnitus Solution Angers Doctors
Tinnitus Terminator
How Matthew Beat Unemployment To Earn $2300 / Week
Fast Cash
Sponsored byEarnify
GW Pharmaceuticals Plc - Get News & Ratings Daily
Enter your email address below to get the latest news and analysts’ ratings for GW Pharmaceuticals Plc with our FREE daily email newsletter:
Copyright © 2016 — Small Cap Wired. All Rights Reserved.
Was in TRTC 1-2 yrs ago. Lost all my $$$$$$. $35,000. They stole it. Paying themselves and employees. Don't get robbed y'all.
Y'all do know GWPH is located in California as well. Buy now. Once California goes legal the US goes legal.
Politics
Q&A New California marijuana czar on pot use: 'It appears there is a medical need'
Lori Ajax
Lori Ajax is the first chief of California's Bureau of Medical Marijuana Regulation. (Handout / California Department of Consumer Affairs)
Patrick McGreevy Patrick McGreevyContact Reporter
Lori Ajax has two years to set up California’s first system to license, regulate and tax medical marijuana. Gov. Jerry Brown recently appointed the Republican to become the first chief of the Bureau of Medical Marijuana Regulation.
Ajax, 51, was previously chief deputy director at the California Department of Alcoholic Beverage Control, where she worked in various positions since 1995. In her new role, she faces a moving target: California voters are likely to vote on an initiative in November that would legalize recreational use of marijuana.
California sets new rules for medical pot industry
California sets new rules for medical pot industry
The measure includes a provision that would transform Ajax’s office into a Bureau of Marijuana Control that would also be responsible for regulating non-medical cannabis, significantly expanding Ajax’s responsibilities. Ajax's office has been loaned $10 million by the state to set up a 25-person bureau that can begin issuing licenses on Jan. 1, 2018.
Ajax sat down Thursday for an interview at her Sacramento office.
ADVERTISING
What about your background has prepared you to oversee the regulation of medical marijuana?
Twenty-one years at the Alcoholic Beverage Control [Department], starting out early on as an agent and then working my way through the ranks. So I dealt with licensing structures and alcohol licenses and enforcement of those licenses in my various positions. And alcohol is a highly regulated product, so I think it is beneficial in setting up this structure for medical cannabis. I think it's going to be helpful. I also had a lot of stakeholder involvement with the public and prevention groups and the industry and law enforcement.
Did you vote in favor of Proposition 215, the measure legalizing medical marijuana, and why?
I don’t remember, to be quite honest with you. That was a long time ago.
Is there a legitimate reason for people to get medical marijuana?
Yes, I do think there is. Unlike regulating alcohol, I’m not a user of marijuana so I am not familiar with how that affects people or what it does. But from the outreach I’ve done since I got here, it appears there is a medical need and I’m tasked with doing this and I’m going to do it. At the end of the day, my opinion shouldn’t matter. This is what was passed into law and I’m going to get this done by Jan. 1, 2018.
You have never used marijuana?
No. I’m not a marijuana user.
California politics updates: Gov. Brown celebrates his 78th, Hahn says Dodgers fans have 'right to watch' Vin Scully's last season
California politics updates: Gov. Brown celebrates his 78th, Hahn says Dodgers fans have 'right to watch' Vin Scully's last season
Do you have a position on the initiative proposed for the November ballot that would allow recreational use of marijuana?
No. Right now I have enough on my plate just dealing with medical marijuana. Of course we have an eye on that ball. I’m of the mind that whether or not that happens, we will deal with that then, and the bureau needs to be nimble enough that we may have to change directions.
What do you need to accomplish between now and 2018 so that the state can begin licensing medical marijuana operations?
A lot. I have on my whiteboard "633 days." It’s a good reminder how it’s actually a short period of time. Last week, I doubled my staff. I have another person that started and we are hiring. In order to get this done, we have to have people. From there we are doing some stakeholder engagement. We are scheduling stakeholder meetings towards the end of this month and in May to go to different areas of the state just to introduce ourselves to people. There will be lots of chances to listen to the industry, listen to the public — whoever wants to attend. And then we are going to get into stakeholder meetings that are more focused on regulation drafting. It’s going to be daunting.
How will you draft the regulations?
Instead of us coming out and drafting it, I think we want to get feedback first, draft it, and then put it out for comment. I think that might be a more efficient way to handle it.
There has been talk that some people are gaming the system, getting medical marijuana cards without having real medical conditions. Do you think that there are some people out there who don’t deserve these cards, and the state should do more to make sure that they are going to people who actually have medical issues?
I don’t have enough information at this point to tell you whether I think that is happening. I think over the course of the next couple of years that is something we are going to have to look at.
Do you know anybody among your relatives and friends who has needed medical marijuana?
I do not. I have heard stories, of course. And through my meetings I’ve set up with industry groups and with legislators, I’ve heard stories of how it has helped folks with cancer.
How do you keep those convicted of serious felonies who were illegal drug dealers from infiltrating the system of growers and sellers?
That’s going to be through our licensing process. We are going to have to do a background, a fingerprint check and then you evaluate the seriousness of the crime at that point.
The federal government still considers marijuana sales and posession a crime. Does it concern you that you are going to regulate something the federal government doesn’t recognize?
I have been tasked with a job to do at the state level and I understand, yes, that there are some concerns at the federal level. But I feel as long as we put in some strong, comprehensive, clear regulations I think we can assure the federal government that we do have a framework in place that will alleviate their concerns. When it comes to regulation, I really feel like if you can minimize the confusion for folks and you just have clear, strong, comprehensive regulations, that’s going to go a long way with the federal government, but of course nobody can predict things.
You face a challenge in operating with state regulations when many cities and counties will have their own, stricter rules. Do you hope the local officials defer to the state rules?
No. The law calls for dual licensing. The locals know best what they want in their cities and counties so I think it is a partnership between us and the locals. I feel its really important for me and the bureau; we need to make sure we stay engaged with the cities and counties. I think it is a good thing, the dual licensing.
Gov. Brown recently said, "The world's pretty dangerous, very competitive. I think we need to stay alert, if not 24 hours a day — more than some of the potheads might be able to put together." Do you have concerns about health risks associated with longterm use of marijuana?
I think a lot of people are concerned about the lack of research on what the effects are of marijuana. I don’t have an opinion on that other than I think we need to have more research and its good that its going to be conducted by the University of San Diego.
patrick.mcgreevy@latimes.com
Follow @mcgreevy99 on Twitter
ALSO
California adopts new rules for medical pot
Legislature sends new medical marijuana rules to governor
Updates from Sacramento
Privacy Policy
Copyright © 2016, Los Angeles Times
Drug Trafficking Jerry Brown
Same boat also. Mdbx. Trtc.
GWPH will do a forward split. It ain't coming back down. We will be living the dream my friend.
U right man. McDonald's payin $9 hour. I'm in medical field. Better jump on that GW$H stock. Medical marijuana.
Amazon way overvalued true. Gonna buy back in when it drops. Watching Bloomberg. Bad earnings coming starting next week. Gonna get ugly.
I'm down here in Florida. Not bad here.
Lebron, u is a smart man
It does when stock market crashes and we in recession. It's coming. Check out global economy. It's time bro.
Guess Not!!!! Everyone must be high today. Hehe
Can I get a ole helllllssss yeah? Dreams coming true. Bout to soar!!!! Any weedlievers out there?
OBAMA will change Sched 1 before he leaves. Has no choice. GW&H blowing up. The US has proven that marijuana has medicinal value. Gonna SOAR
What up Lebron. Smart move. I got burnt to. Christmas time. All that was bought on Amazon. Not this time. I'm out. TIMBER. Market crashing. But it will go back up after it gets down to around $300-$400.
Market crashing. Can't keep GWPH down. Gonna SOAR
Got to buy those dips.
No choice but to get it off Sched 1. GWPH has proven that marijuana has medical properties here in the US. FDA bound baby.
Epidiolex the first drug with many more to come. GWPH has bought up a lot of patents over past 20 years. It's there turn to shine. Move over Pfizer. Get in while the shares are cheap. Splits coming end of the year.
NY Daily News
U.S.
DEA considers dropping marijuana from 'most dangerous' group
CHRISTOPHER BRENNAN
NEW YORK DAILY NEWS Updated: 04/06/2016 10:59 PM ET
facebook83
Tweet
email
The Drug Enforcement Administration has said it will make a decision about reclassifying marijuana during the first half of this year. Above, DEA head Chuck Rosenberg, who has called medical marijuana "a joke."ALEX BRANDON/AP
The Drug Enforcement Administration has said it will make a decision about reclassifying marijuana during the first half of this year. Above, DEA head Chuck Rosenberg, who has called medical marijuana "a joke."
After years high atop the Drug Enforcement Administration’s list of the most dangerous drugs, marijuana may soon be coming down.
The DEA said it will likely decide in the first half of 2016 whether to reclassify cannabis in a category other than Schedule 1, a group that includes heroin and is said to have no medical purpose but "potentially severe psychological or physical dependence."
Though a Gallup poll from last year shows that 58% of Americans want weed legal for recreational use, the drug remains completely illegal under federal law and officials’ upcoming decision is unlikely to change that.
However, reclassifying marijuana from Schedule I to Schedule II, which includes drugs such as cocaine, would make it much easier for researchers to learn about its effects, medical and otherwise.
Currently all the marijuana used for research purposes is grown by the University of Mississippi, according to a letter from the DEA first obtained by the Huffington Post, though in 2015 this included only 20 shipments to eight researchers.
The American Medical Association has said that the Schedule I status would be reviewed “with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines.”
The Schedule I classification, set in 1970, has created a dearth in science about marijuana, even as state laws around cannabis have changed rapidly with shifting attitudes.
The DEA teasing a decision about the comes after a group of Democratic senators, including Elizabeth Warren and Kirsten Gillbrand, asked it and other federal bodies to create a research strategy because of the growing patient pool of medical marijuana users.
NRDMITRIY NOROV/GETTY IMAGES/VETTA
The potential move would make research on the plant's effects easier, though the DEA has previously rejected petitions for the change.
Twenty-three states have legalized some form of medical marijuana, with Alaska, Colorado, Oregon, Washington and the District of Columbia allowing recreational use.
The head of the DEA, however, has voiced strong opposition to the strain of thought that marijuana has medical benefits.
“What really bothers me is the notion that marijuana is also medicinal — because it's not,” DEA head Chuck Rosenberg said in November.
“We can have an intellectually honest debate about whether we should legalize something that is bad and dangerous, but don't call it medicine — that is a joke.”
In 2001 and 2006 the DEA rejected petitions to reclassify marijuana to something other than Schedule I.
Follow on Twitter @CKozalBrennan.
cbrennan@nydailynews.com
Read More
JOIN THE
CONVERSATION: facebook
twitter
email
Sponsored Links PROMOTED STORIES
The 4 stages before a Heart Attack. Are you at risk?
VitaPulse Supplement
Shocking Photos That Will Change Your Views on History
Buzzamin
Julia Roberts' Marriage In Trouble After Husband Caught Slipping
Hollywood Hiccups
She Was Alone In The Elevator With Her Dog. I’m Shocked By What The Camera Caught.
Little Budha
Tips For Your Panama City Beach Trip
Visit Panama City Beach
Ridiculously Huge Celebrity Houses - Can't even believe #4
Weekend Collective
by Taboola
Paid Content By
Mortgage rates fall to new low - 3.13% APR
$225K for $904/mo. No points. Get multiple mortgage offers in minutes. Can’t hurt to look. It’s free
More Articles
Burger King at 20 Willowbrook Rd. in Staten Island.
N.J. man dies after being found in car in Staten Island
A 34-year-old man died after being found in a car in Staten Island Wednesday night, cops said.
PHILADELPHIA, PENNSYLVANIA - APRIL 06: A supporter of Democratic presidential candidate Sen. Bernie Sanders (D-VT) at a rally at Temple University on April 6, 2016 in Philadelphia, Pennsylvania. The Pennsylvania Democratic Primary is scheduled for April 26, 2016. (Photo by Jessica Kourkounis/Getty Images)
Bernie Sanders slams Hillary Clinton as unqualified
Democratic presidential hopeful Bernie Sanders on Wednesday called Hillary Clinton unqualified to sit in the Oval Office.
Heroic FDNY members with Ladder Company 58 – Firefighter Ryan R. Bourke, Lieutenant Andrew B. Bowman, Firefighter Christopher J. Reilly, Firefighter John P. Daly Jr., Firefighter William H. Smith, Firefighter Thomas J. Wutz Jr.
Firefighter braves burning Bronx bedroom to save elderly man
A selfless firefighter navigated smoke and flames climbing the walls of a Bronx bedroom to save an elderly paraplegic man's life Wednesday.
Police on the scene at 401 East 80 street [The Gracie Mews] where an unidentified male jumped or fell to his death.(Sam Costanza for New York Daily News)
Man, 36, falls to his death from Manhattan high-rise
A 36-year-old man plunged to his death from an Upper East Side high-rise Thursday night.
Former NYPD Chief of Department Philip Banks (center) traveled overseas with businessmen Jeremy Reichberg (left) and Jona Rechnitz (right). (Photo by Baruch Ezagui)
NYPD cops under scrutiny for taxpayer-funded Midwood feast
The FBI is looking into three businessmen who allegedly sought to curry favor with high-ranking cops.
Show 5 more
H To the top
Site Map Services Contact Us
Terms of Service Privacy Policy
Hey wingman. My wife showed me how to copy the site. See it now? I also publicly apologize for calling u an idiot. Just frustrating to see people not see what's happening here. This is gonna happen. I'm in medical field. Mayo Hosp begging to use medical marijuana for there cancer pts right now. But they can't. I have pts that smoke marijuana to relieve pain when no other pain pills, opioids , nothing will work.
Go to Your Daily Yahoo. It's under the pict of Berney sanders and his wife.
Been cheering since $8.76 a share. Just trying to get idiots like u that don't believe to buy the future and retire like I am going too. But u can keep shorting if u like.
It's on Yahoo front page. Why u think it's going up? Check it. Buy it while u can.
It ain't coming back down.
DEA meeting to reschedule marijuana from Sched 1 mid year. Gonna SOAR
Guess what? Bout to SOAR again. Just out: DEA to discuss removing marijuana off Sched 1 mid year.
What we all been waiting for.
No stopping GWPH now. FDA approval coming. Not many shares avail. Buy these cheap shares now. Will wake up at 7 am one morning and pps will be up $50. Just like last month.
Brings chills to my spine brother. 20 years in the making. Time to reward the cannibis weedlievers.
SOARING now. Buy these cheap shares now.
Google Epidiolex news. It's all over the Internet. Stories of all the kids successful treatments. Children Hospitals all for Epidiolex. Gonna SOAR. Take 2nd mortgage out now and get as many shares as u can.
There's another 4000 shares sold. Gonna get burned. Guess they happy wit lil bit $$$$$$$. Gonna miss the big one.
Who in there right mind would sell 3800 shares at this time. All hedgies selling. Hold on to your shares normal investors like me. Buy the dips when those idiots sell there's. Remember they bought shares at $8.
Absolutely. I saw that. Obama and Congress gonna have to take marijuana off Sched 1 drug. Move it to a 2 or 3. Then FDA will approve it. Just putting more pressure on them.
Also, protest in Washington Saturday in front of Whitehouse. Lots of marijuana smoking. Lots of arrest coming. Obama will resched marijuana before he leaves office.
Yes. It's passed. Ain't no law suits. Hedgies just scaring people. Can't scare us no mo. We eaglizing. FDA coming baby. Obama will change Sched of marijuana and leave his legacy and go in the history books for life. This is to easy $$$$$.
Also Zacks has it at a buy. Target price $140-$179. They giving us this mannnnnn. Take it. Gonna Soar.
Yeah. My news I put out. Wake up people. No Brainer. Buy now. News will come out at 7 am and it will already be up $50 share. Gonna Happen AGAIN!!!
OMG. I hope it does. 2nd mortgage on my home to buy at those prices. $170 next run up. People, epidiolex passed phase 3. No drug out there in the world for these type seizures. They got to have something. No Brainer.
Y'all know pps going to $150 share when phase 3 results come out again in June. I know everyone and investors like me know that. Got to be hedgies selling to scare us again to sell our shares. Ain't happening!!!!! Buy the dips.
Gonna SOAR today. Short squeeze.